EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
Background One of the most malignant tumors in men is prostate cancer that is still incurable
due to its heterogenous and progressive natures. Genetic and epigenetic changes play …
due to its heterogenous and progressive natures. Genetic and epigenetic changes play …
Survival with olaparib in metastatic castration-resistant prostate cancer
Background We previously reported that olaparib led to significantly longer imaging-based
progression-free survival than the physician's choice of enzalutamide or abiraterone among …
progression-free survival than the physician's choice of enzalutamide or abiraterone among …
NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …
prostate cancer diagnosis and include management options for localized, regional, and …
Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial
P Sharma, RK Pachynski, V Narayan, A Fléchon… - Cancer cell, 2020 - cell.com
Metastatic castration-resistant prostate cancer (mCRPC) is immunologically" cold" and
predominantly resistant to immune checkpoint therapy due to few tumor-infiltrating T cells …
predominantly resistant to immune checkpoint therapy due to few tumor-infiltrating T cells …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Summary Background Lutetium-177 [177 Lu] Lu-PSMA-617 is a radiolabelled small
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C Parker, E Castro, K Fizazi, A Heidenreich… - Annals of …, 2020 - annalsofoncology.org
Subclinical prostate cancer is common in men> 50 years. Population-based screening of
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …
Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms
H Tukachinsky, RW Madison, JH Chung… - Clinical Cancer …, 2021 - AACR
Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with
metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to …
metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to …
Advanced prostate cancer: treatment advances and future directions
Prostate cancer affects one in every nine men in the USA and is the second leading cause of
cancer-related death. The treatment landscape of advanced prostate cancer is changing …
cancer-related death. The treatment landscape of advanced prostate cancer is changing …